Mission Statement, Vision, & Core Values of Biotricity, Inc. (BTCY)

Biotricity, Inc.'s Mission and Vision aren't just aspirational text; they are clearly mapped to the company's operational wins, like the $13.8 million in revenue for fiscal year 2025 and the first-ever positive Adjusted EBITDA of $438,260 in Q4-FY25. When a Technology-as-a-Service (TaaS) company can lift its gross margin to 76.6% while focusing on remote patient monitoring, you have to ask: how much of that efficiency is driven by their core values around AI-driven automation? Does the stated mission-to hold an individual's hand throughout their cardiac journey-defintely translate into the predictable $12.6 million in recurring technology fees that sophisticated investors value? We'll break down the strategic alignment between their foundational principles and their financial trajectory.

Biotricity, Inc. (BTCY) Overview

You're looking for a clear picture of Biotricity, Inc. (BTCY), a company that's quietly making waves in the remote patient monitoring space, and the numbers from the 2025 fiscal year tell a story of deliberate, margin-focused growth. The company is a Technology-as-a-Service (TaaS) provider, meaning they focus on recurring subscription revenue, not just one-time device sales, which is a much more stable model. They are defintely a high-growth player in a competitive market.

Biotricity, founded in 2010 with headquarters in Redwood City, California, specializes in medical diagnostic and consumer health monitoring solutions, primarily for cardiovascular and chronic conditions. Their business model is simple: bridge the gap between hospital-grade monitoring and everyday life. Key products like Bioflux, a Mobile Cardiac Telemetry (MCT) device, and Biocare Telemed, a chronic care management platform, generate revenue through device leases and, more importantly, recurring monitoring service fees. For the full Fiscal Year 2025, which ended March 31, 2025, the company reported total revenue of $13.8 million, marking a 14.3% growth year-over-year.

Here's the quick math on their revenue mix:

• Total FY 2025 Revenue: $13.8 million
• Recurring Technology Fees: $12.6 million
• Technology Fees are over 10.5 times Device Sales revenue

Fiscal Year 2025 Financial Performance: Margin Expansion and Operational Turnaround

The latest financial reports, including the Q2 Fiscal Year 2026 results (ending September 30, 2025), show a significant operational shift. For the six months ended September 30, 2025, total revenue hit $7.76 million, up from $6.47 million in the prior year period, driven by both technology fees and device sales. This isn't just revenue growth; it's profitable growth.

The real highlight is the gross margin expansion. In Q2 FY26, gross profit increased by 29.4% to $3.2 million, pushing the gross profit margin to an impressive 81.9%. This is a direct result of leveraging proprietary Artificial Intelligence (AI) for workflow automation and focusing on those high-margin recurring technology fees. This operational discipline is translating to the bottom line: the company reported a positive Profit (Loss) from Operations of $0.56 million for the six months ended September 30, 2025, a major turnaround from a $1.42 million loss in the previous year.

The net loss is shrinking fast. The Net Loss Attributable to Common Stockholders for the six-month period was $(1.53) million, a substantial reduction from the $(8.60) million loss in the comparable prior-year period. The company also achieved its second consecutive quarter of positive Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) at $373,000 in Q2 FY26. They are moving toward scalable profitability.

Biotricity's Position in the Remote Monitoring Industry

Biotricity is establishing itself as a leader in the remote monitoring segment of preventative care. Their focus on high-quality, doctor-friendly support and accurate diagnostics has helped them secure strategic alliances with Group Purchasing Organizations (GPOs) that collectively represent 90% of all hospitals in the US. That kind of market access is a serious competitive advantage.

While the company is smaller, with a market capitalization around $14.4 million as of mid-November 2025, it competes directly with larger players like iRhythm Technologies and BioTelemetry (a Philips company). The strategy is clear: use their TaaS model and high gross margins to fuel further product development, like the commercialization of their Bioflux, Biocore, and Biocare product lines. If you want to dive deeper into the mechanics of their business, you should check out Biotricity, Inc. (BTCY): History, Ownership, Mission, How It Works & Makes Money to understand why this model is so successful.

Biotricity, Inc. (BTCY) Mission Statement

You're looking for the core engine driving Biotricity, Inc., and it's simple: the mission is to close the dangerous gaps in cardiac care by giving both patients and doctors a complete, cohesive view of health data, moving beyond disjointed diagnostics to full chronic care management. This focus isn't just a marketing slogan; it's the foundation of their Technology-as-a-Service (TaaS) model, which helped drive a 14.3% revenue growth in fiscal year 2025 (FY25), reaching $13.8 million.

A mission statement is the operational compass for a company, especially in a high-stakes sector like healthcare technology. For Biotricity, it guides every capital allocation decision, from product development to strategic partnerships. Honestly, the mission is what transforms a medical device company into a sustainable, recurring revenue business, which is why their Technology Fees grew to $12.6 million in FY25.

Component 1: Holding an Individual's Hand Through the Cardiac Journey

The first core component is deeply empathetic: to hold an individual's hand throughout their cardiac journey. This means Biotricity isn't just selling a one-time diagnostic device, like a Holter monitor; they are building a continuous, end-to-end support system. The market reality is that cardiac care is often disjointed, leaving patients vulnerable after the initial diagnosis.

Their solution is a meticulously expanded portfolio that offers a cohesive view of an individual's health. This commitment is what underpins their move into chronic care management (CCM) solutions, which are crucial for long-term patient outcomes and, for the company, for securing that valuable recurring revenue stream. This approach is defintely a key reason for their sustained record of strong customer retention.

Component 2: Leveraging Technology-as-a-Service (TaaS) and Predictive AI

The second pillar is technological innovation, specifically the integration of connected medical devices, big data, and predictive Artificial Intelligence (AI). Biotricity's vision is clear: the future of healthcare lies in this connected ecosystem, which delivers faster analytics for better care delivery. This is a realist's view of how to scale quality in a capital-intensive industry.

Here's the quick math on why this matters: their recurring Technology-as-a-Service (TaaS) fees accounted for $12.6 million of the total $13.8 million in FY25 revenue, representing over 10.5 times their Device Sales revenue. That high-margin revenue base is a direct result of their TaaS model. Plus, their proprietary Cardiac AI Cloud platform is already leveraging over a trillion beats of anonymized data, which is the fuel for pursuing FDA clearance for a groundbreaking AI clinical model. You can read more about the financial implications of this model here: Exploring Biotricity, Inc. (BTCY) Investor Profile: Who's Buying and Why?

Component 3: Delivering High-Quality, Scalable Diagnostics

The third component is an operational commitment to high-quality, scalable diagnostics that bridge the gap between diagnostic care and disease management. This isn't just about having a great product; it's about making sure it's reliable, accurate, and accessible to the largest possible number of providers.

The numbers show this commitment is paying off in operational efficiency and market penetration:

• Gross margins improved significantly to 76.6% for FY25, up from 69.3% in the prior year, directly reflecting efficiencies gained from proprietary AI in operational automation.
• The margin expansion continued into Q2 of fiscal 2026 (ended September 30, 2025), reaching a gross margin of 81.9%.
• Biotricity has secured strategic alliances with three of the top Group Purchasing Organizations (GPOs), which collectively represent 90% of all hospitals in the US.

What this estimate hides is the operational rigor needed to achieve their first-ever positive Adjusted EBITDA of $438,260 in Q4-FY25, a clear sign that the high-quality service model is translating into financial health. This focus on diagnostic accuracy and user-friendly solutions is what sustains their strong customer retention.

Biotricity, Inc. (BTCY) Vision Statement

You're looking at Biotricity, Inc. (BTCY) right now and trying to gauge its long-term potential beyond the latest earnings report. The company's vision is your roadmap, telling you exactly where they plan to invest capital and focus their Technology-as-a-Service (TaaS) model. It's a very clear push into a fully connected, AI-driven healthcare future, moving past simple remote monitoring to predictive diagnostics.

The Mission, simply put, is to 'hold an individual's hand throughout their cardiac journey,' which means they are building a complete, cohesive ecosystem of solutions, not just selling one-off devices. This strategic focus is why their recurring Technology Fees hit $12.6 million in the 2025 fiscal year, growing 12% year-over-year and representing a strong, predictable revenue stream. That's a defintely solid foundation.

Connected Medical Devices and Data Leverage

The first pillar of Biotricity's vision is the belief that the future of healthcare rests on connected medical devices that produce data leveraged by both physicians and individuals. This isn't just about a doctor getting an alert; it's about democratizing the data so the patient can be a more active participant in their own care. This means their core product, the Biocore Pro cardiac monitor, is designed for ease of use and high data fidelity.

For the 2025 fiscal year, this focus on a subscription-based, data-centric TaaS model helped drive total revenue to $13.8 million, a 14.3% increase from the previous year. The recurring nature of this revenue is key. It means they aren't relying on a one-time hardware sale; they are selling a long-term data service. This is why you see them expanding their reach into new verticals like sleep and pulmonology, diversifying the data they can collect and monetize.

Integration with Predictive AI and Machine Intelligence

The vision quickly moves past simple data collection to integration with big data, predictive AI, and machine intelligence. This is the high-margin, high-value component. The goal is to use their massive dataset-built on over a trillion beats of anonymized data-to move from diagnostic to predictive care. They want to flag a risk before it becomes an event.

This commitment to operational efficiency through proprietary AI-driven automation is a major reason for their margin expansion. Here's the quick math: Gross margin for the 2025 fiscal year improved significantly to 76.6%, up from 69.3% in the prior year. That's a jump of 8.9% in margin, which directly reflects the efficiency gains from using AI in their workflow optimizations, as seen in their Q4-FY25 gross margin hitting 80.4%. You can learn more about the investors who are betting on this strategy at Exploring Biotricity, Inc. (BTCY) Investor Profile: Who's Buying and Why?

Better and Faster Care Delivery

The final outcome of their vision is to create better and faster analytics for better and faster care delivery. This is the patient-outcome and cost-saving part of the equation. By providing clinicians with deeper, more accessible insights, they enable quicker interventions, which is critical for high-risk conditions like Atrial Fibrillation.

The financial impact of this operational and technological discipline is clear: the company's net loss was reduced by 20% year-over-year in FY2025, dropping to $11.9 million from $14.9 million in FY2024. Even more telling, they achieved a positive Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $438,260 in the fourth quarter of FY2025-the first time in company history. This shows the model is finally hitting an inflection point of scale and efficiency.

The near-term risks are always around execution and regulatory hurdles, but the strategic actions are clear:

• Expand the commercial team to capture rising demand.
• Secure regulatory approval in key international markets (like Canada, Saudi Arabia, and Argentina).
• Develop the next-generation multi-parameter cardiac monitor.

Core Values: Operationalizing the Vision

While not a traditional list of platitudes, Biotricity's core values are evident in their operating principles. They are a Technology-as-a-Service company, meaning they prioritize recurring revenue and customer retention. Their values map directly to their strategic execution:

• Innovation: Continuously developing next-generation diagnostic technologies, like the Biocore Pro.
• Efficiency: Sharpening operational execution through AI-driven automation to maintain high margins.
• Scalability: Building a model that can support growth across multiple fronts, including cardiac, sleep, and pulmonology.

What this estimate hides is the continued need for investment in their commercial team to fully capitalize on the market demand. But the focus on driving growth while maintaining margins above 75% is a strong signal of financial discipline. Your next step should be to monitor their Q3-FY26 results for sustained positive Adjusted EBITDA, as that confirms the scalability of this model.

Biotricity, Inc. (BTCY) Core Values

You're looking for the real drivers behind Biotricity, Inc.'s recent financial performance, not just the revenue numbers. The core values-the company's cultural DNA-are what translate its mission to revolutionize remote monitoring into tangible results, like the impressive margin expansion we saw in fiscal year 2025. It's all about mapping its strategic intent to clear, measurable actions.

Biotricity's mission is to hold an individual's hand throughout their cardiac journey, which is a very human way to describe their goal of creating a cohesive, end-to-end view of a patient's health. Their vision is a future where connected medical devices, big data, and predictive Artificial Intelligence (AI) deliver faster, better care. This focus boils down to three key core values that guide their capital allocation and operational choices.

If you want a deeper dive into the company's foundational structure, you can check out Biotricity, Inc. (BTCY): History, Ownership, Mission, How It Works & Makes Money.

Patient-Centric Innovation

Innovation isn't just a buzzword here; it's the engine driving their Technology-as-a-Service (TaaS) model, but it's always centered on the patient's outcome. Biotricity is defintely not just selling hardware; they are selling continuous, intelligent monitoring. This value shows up directly in their commitment to Research and Development (R&D) and product rollout.

The company's focus on connected medical devices means they are constantly enhancing their diagnostic capabilities. For example, the rapid adoption of their next-generation cardiac monitoring device, Biocore Pro, is a direct result of this focus. Also, the expansion of their Cardiac AI Cloud platform, which leverages over a trillion beats of anonymized data, is positioned to enhance clinical profitability and patient outcomes simultaneously. That's how you make innovation pay off.

• Launched Biocore Pro for next-gen cardiac monitoring.
• Expanded Cardiac AI Cloud platform using massive data sets.
• Targeting a total addressable market of $35 billion.

Operational Excellence and Financial Discipline

A good mission means nothing if the business model isn't sustainable. This core value is all about doing more with less, especially as the company scales its recurring revenue base. Biotricity has been laser-focused on automation and efficiency, which is the smart way to grow in a capital-intensive industry.

Here's the quick math on their discipline: For the fiscal year ended March 31, 2025, Biotricity reduced its operating expenses by a substantial 24.5% year-over-year. This, combined with revenue growth of 14.3%, helped drive a significant margin improvement. The company achieved a Gross Margin of 76.6% for FY2025, a jump from 69.3% in the prior year. This relentless pursuit of efficiency led to a major milestone: the first-ever positive Adjusted EBITDA of $438,260 in the fourth quarter of FY2025. That's a clear signal of a business model reaching an inflection point.

Commitment to Quality and Accuracy

In healthcare, quality isn't optional; it's a life-or-death decision. This value is foundational to Biotricity's reputation with physicians and patients. The company's focus on high-quality support services and accurate diagnostics is what drives customer retention, which is essential for a subscription-based model.

The clearest demonstration of this commitment in 2025 is the company's plan to pursue FDA clearance for its groundbreaking AI clinical model. Seeking regulatory validation for an AI-driven diagnostic tool shows a commitment to the highest standard of clinical accuracy, not just speed. Furthermore, their high customer retention rate is a qualitative measure of their success in providing provider-friendly support and user-friendly solutions. This attention to detail ensures that the data collected-which is the core of their value proposition-is trustworthy and actionable for clinicians, ultimately improving patient outcomes.